Alimonti A

Institute of Oncology Research (IOR), Bellinzona, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland; Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland; Department of Medicine, University of Padova, Padova, Italy; Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.

1 paper · ORCID

ArticlePsilocybin

Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms.

Colognesi M, Gabbia D, Signor A +30

Europe PMC2026